Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (30089)	1/10/2000 5:39:00 PM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 32384

>large list of side effects, such as elevated cholesterol, >severe headaches, and hypothyroidism. The side-effect >profile could reduce the optimism about using Targretin to >treat other cancers with larger market sizes, such as >breast cancer. None of the three side effects listed are likely to discourage someone with ABC.Someone should send this guy a copy of the 5 and 10 year survival rates for breast cancer.Sure, the patient might have to take drugs to lower cholesterol and to treat the hypothyroidism, but those drugs are on the market. That leaves the severe headaches and there are some pretty good drugs on the market for those too. Just compare the side effects to those of traditional chemotherapy for breast cancer and I think the choice is obvious. Forget this guy; he's off base. That said, I'm still waiting for major news. We need something positive to sustain todays elevation.I'd be happy with something that would allow us to form a nice base at $15 so that we can get whatever loose shares at that level swept up. Ligand has come far pretty fast and a nice basing action seems desirable. Thanks, Torben